insights_auto
Kwa nini 4547 imepungua kwa 3.39%?
Fahamu zaidichevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥ 3,700.00
arrow_downward
-3.39%(-130.00) Siku 1
2 Okt, 15:30:00 GMT +9 · JPY
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya 4547...
Fungua
JP¥ 3,810
Juu
JP¥ 3,815
Chini
JP¥ 3,690
Mtaji wa soko
172.21B
Wastani wa kiasi cha mauzo
elfu 66.55
Kiasi cha mauzo ya hisa
elfu 97.50
Gawio
3.24%
Mgawo wa faida wa kila robo mwaka
JP¥ 30
Tarehe ya kutojumuisha gawio
29 Sep 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
10.97
Juu kwa wiki 52
JP¥ 5,040
Chini kwa wiki 52
JP¥ 3,500
EPS
JP¥ 337
Hisa za wawekezaji
46.72M
Idadi ya wafanyakazi
elfu 2
Fungua
JP¥ 3,810
Juu
JP¥ 3,815
Chini
JP¥ 3,690
Mtaji wa soko
172.21B
Wastani wa kiasi cha mauzo
elfu 66.55
Kiasi cha mauzo ya hisa
elfu 97.50
Gawio
3.24%
Mgawo wa faida wa kila robo mwaka
JP¥ 30
Tarehe ya kutojumuisha gawio
29 Sep 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
10.97
Juu kwa wiki 52
JP¥ 5,040
Chini kwa wiki 52
JP¥ 3,500
EPS
JP¥ 337
Hisa za wawekezaji
46.72M
Idadi ya wafanyakazi
elfu 2
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Investing News Network
·
dakika 7 zilizopita
New York Giants at NYSE for 40th Anniv. of Super Bowl XXI: NYSE Content Update
01net
·
dakika 9 zilizopita
Powerus Completes Merger, Rings Opening Bell, Now Trading as PUSA on Nasdaq
Foreign Policy Journal
·
dakika 25 zilizopita
Bitmine Immersion Technologies (NASDAQ: BMNR) Forms Golden Cross As Ethereum Holdings Surpass 6 Million Tokens
Yahoo Finance
·
dakika 29 zilizopita
1 S&P 500 Stock to Research Further and 2 Facing Headwinds
Wasifu
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Kuhusu Kissei Pharmaceutical Co Ltd
Afisa Mkuu Mtendaji (CEO)Mutsuo Kanzawa
Wafanyakazielfu 1.79
Lilianzishwa9 Ago 1946
Makao makuuMatsumoto, Mkoa wa Nagano, Japani
Sekta-
Tovutikissei.co.jp